US Patent 8,557,852 Scope of Claims and US Patent Landscape for Polymorph-Based Venous Thrombosis Prevention/Treatment
Executive summary
US 8,557,852 is a US method-of-treatment patent that claims preventing or treating venous thrombosis, including deep venous thrombosis, by administering a therapeutically effective amount of a specific “salt” (Formula II) constrained to a defined crystalline polymorph state. The claim scope is driven by (1) the defined Formula II salt, (2) polymorph identity confirmed by powder X-ray diffraction (XRPD) peak locations and (3) optional thermal characterization confirmed by differential scanning calorimetry (DSC) patterns. Independent claim coverage is for therapeutic methods; dependent claims broaden/operationalize formulation and analytical characterization requirements.
This patent is structurally positioned to block generic or alternative-manufacturing entry unless challengers can practice the same method using a salt that satisfies the same polymorph/solid-state identity (or argue non-infringement via different polymorph and/or different XRPD/DSC characteristics). The main freedom-to-operate (FTO) risk is not just “the API salt,” but “the polymorph and how it’s defined.”
What does US Patent 8,557,852 claim for venous thrombosis treatment and prevention?
Core answer: It claims methods of preventing or treating venous thrombosis in mammals by administering a therapeutically effective amount of a defined Formula II salt that is in a crystalline polymorph form, with polymorph identity supported by XRPD and DSC.
Claimed indication coverage
- Venous thrombosis (broad): Claim 1.
- Deep venous thrombosis (DVT) (explicit): Claim 7.
These are method-of-use claims. They do not claim a device, kit, or anticoagulant class per se. The infringement theory depends on administering the claimed polymorph salt for the claimed therapeutic purpose.
Claimed active ingredient scope (what is being administered?)
- A salt represented by Formula II.
- The salt must be “in a crystalline polymorph form.”
Because the claims you provided reproduce “Formula II” without the chemical name/structure, the scope analysis here is limited to claim mechanics rather than compound identity. In practice, Formula II is a gatekeeper: any non-Formula-II compound is outside literal claim scope.
Claimed therapeutic scope (how is the method practiced?)
- Administering a therapeutically effective amount of the polymorph salt.
- Claims 2 and 8 add an optional formulation route: administration as a pharmaceutical composition comprising the salt and a pharmaceutically acceptable carrier.
Which claims in US 8,557,852 define the polymorph scope using XRPD peak lists?
Core answer: Claims 3-5 and 9-11 define the crystalline polymorph by XRPD peak locations (at least four or at least eight peaks from specified sets), plus optional “approximate to” a reference pattern (FIG. 1A).
Dependent claims driven by XRPD peak inclusion tests
Claims are structured around minimum peak-count thresholds and allowed peak positions (degrees 2θ at 20 units as recited in the claim text).
XRPD “at least four” peaks
- Claim 3 (venous thrombosis, independent anchor Claim 1):
- At least four approximate characteristic peak locations selected from:
- 4.9, 9.7, 13.8, 14.1, 15.2, 17.6, 18.5, 20.8, 21.6, 22.7, 24.1, 26.3, 26.8 degrees 2θ.
- Claim 9 mirrors for deep venous thrombosis (dependent on Claim 7).
XRPD “at least eight” peaks
- Claim 4:
- At least eight approximate characteristic peak locations selected from:
- 4.9, 9.7, 11.8, 13.8, 14.1, 15.2, 17.6, 18.5, 19.9, 20.8, 21.6, 22.7, 24.1, 25.0, 26.3, 26.8 degrees 2θ.
- Claim 10 mirrors for deep venous thrombosis.
Reference-pattern “approximate to” coverage
- Claim 5 (Claim 1 dependent):
- XRPD pattern is “approximate to” the powder X-ray diffraction pattern shown in FIG. 1A.
- Claim 11 (Claim 7 dependent):
- Same FIG. 1A “approximate to” construct.
Practical claim effect: An alleged infringer can seek non-infringement by demonstrating its marketed polymorph does not match the required peak set criteria or does not “approximately” match FIG. 1A under the agreed analytical methodology. Conversely, the patentee can argue that small shifts or measurement variation still satisfy “approximate” peak positions.
Key scope characteristic
These XRPD claims do not require every listed peak; they require minimum peak counts drawn from approved peak positions. That makes the XRPD identity definition broad enough to tolerate partial correspondence but narrow enough to exclude substantially different polymorphs.
How does US 8,557,852 use DSC to lock in polymorph identity?
Core answer: Claims 6 and 12 add optional DSC pattern constraints “approximate to” FIG. 2A.
- Claim 6 (dependent on Claim 1):
- DSC pattern approximate to FIG. 2A.
- Claim 12 (dependent on Claim 7):
- Same FIG. 2A DSC constraint.
Practical claim effect: DSC typically corroborates polymorph form or solid-state transitions. Because these are dependent claims, they likely strengthen infringement arguments when the same polymorph is characterized across XRPD and DSC.
Is the patent limited to crystalline polymorphs or any polymorph?
Core answer: It is limited to a salt in a crystalline polymorph form, but the claim text you provided does not specify polymorph “Form A/B” names. Instead, it defines acceptable polymorph identity through XRPD/DSC criteria in dependent claims.
Claim hierarchy implications
- Independent claims (1 and 7) require:
- Formula II salt
- in a crystalline polymorph form
- used in therapeutic method to treat/prevent venous thrombosis / DVT.
- Dependent claims narrow or define the polymorph via:
- XRPD peak inclusion thresholds (Claims 3-5 and 9-11)
- DSC pattern “approximate to” FIG. 2A (Claims 6 and 12)
Litigation posture this enables
- If a defendant’s polymorph fails the XRPD inclusion tests, the patentee can still attempt to prove infringement under the independent claims by arguing the administered polymorph is within the required “crystalline polymorph form” interpretation, but dependent claims provide a clean factual framework anchored to measurable signatures.
What are the “method of use” claim boundaries for a generic or alternative-polymorph entry?
Core answer: A generic product can avoid literal infringement if it does not contain the same Formula II salt in the claimed crystalline polymorph state as defined (especially under XRPD “peak list” criteria).
Likely non-infringement levers
- Different salt identity: If the product uses a different salt form not covered by Formula II.
- Different polymorph: If the polymorph differs such that the XRPD peak set does not meet:
- at least four peaks from the Claim 3 set or
- at least eight peaks from the Claim 4 set
- and/or does not “approximately” match FIG. 1A.
- Manufacturing-induced polymorph conversion: If the product is stored/processed in a way that results in a different solid-state form at the time of administration, the XRPD signature may differ.
- DSC mismatch: If XRPD is borderline, DSC mismatch (Claims 6/12) can be used to argue lack of polymorph equivalence.
Likely infringement theories
- Direct method-of-use infringement where the accused product is administered for venous thrombosis or DVT.
- Solid-state identity proofs using XRPD and DSC, particularly to hit dependent claims.
What formulations are protected by US 8,557,852?
Core answer: The patent protects pharmaceutical compositions that include the claimed polymorph salt plus a pharmaceutically acceptable carrier, but only as part of the claimed method-of-treatment context (dependent claims 2 and 8).
Formulation claim mechanics
- Claim 2: method of claim 1 where salt is administered as a pharmaceutical composition comprising:
- polymorph salt
- pharmaceutically acceptable carrier
- Claim 8: same concept tied to deep venous thrombosis.
Boundary: The claims you provided do not list excipients, dosage forms (tablet, capsule, IV, etc.), or release characteristics. The carrier is broad, so formulation design typically focuses on maintaining or avoiding the claimed polymorph.
How does the claim language “approximate to” affect scope and proof?
Core answer: “Approximate to” creates flexibility and makes infringement depend on experimental reproducibility and expert interpretation of XRPD/DSC similarity.
Why it matters for XRPD
XRPD measurements vary with:
- sample preparation (particle size, hydration)
- instrument configuration
- background subtraction and peak picking algorithms
- temperature and humidity
Because the claims require “approximate characteristic peak locations,” the patentee can argue measurement variation still falls within “approximate.” The defendant will seek to show the accused peaks lie outside the “approximate” window or that the accused pattern lacks the required minimum peak count selection thresholds.
What is the strength profile of US 8,557,852’s claim set (scope vs. defensibility)?
Core answer: The estate’s strength is linked to how specifically it defines the polymorph. Strong points are measurable XRPD/DSC constraints; vulnerability points are dependence on expert interpretation of “approximate” and the possibility of alternative polymorph non-infringement.
Strength factors
- Measurable identifiers:
- XRPD peak location lists and minimum peak counts
- DSC “approximate to” FIG. 2A
- Direct therapeutic method claims aligned with clinical use and generic labeling.
Potential weaknesses for challengers
- The claim structure does not require a named polymorph label. It relies on analytical identity, which can make “form switching” harder if the generic still crystallizes into a form that matches the claimed signatures.
- Dependent claims offer multiple independent factual anchors (Claim 3/4 peak lists; Claim 5/11 FIG. 1A; Claim 6/12 FIG. 2A).
What does this mean for generic launch risk and Paragraph IV strategy?
Core answer: The key risk for generic applicants is that a successful product will still fall within the claimed polymorph definition, even if the applicant selects a different manufacturing route or starts from a different polymorph seed, because final product can crystallize into the claimed form.
Generic entry scenarios to evaluate (conceptually)
- Scenario A: Same polymorph despite process change
- Highest infringement risk. XRPD/DSC likely match.
- Scenario B: Different polymorph at release
- Lower risk if XRPD peak thresholds are not met.
- Scenario C: Polymorph conversion after storage
- Risk returns if the administered material converts into the claimed polymorph before or during use.
- Scenario D: Product is a mixture
- May still satisfy “at least four” or “at least eight” peak criteria if the claimed polymorph component is present at sufficient intensity.
The claim set as written does not expressly require “substantially pure” polymorph, so a mixture argument may arise depending on how the patentee defines “salt is in a crystalline polymorph form.”
What other patents usually matter around this type of polymorph-based method patent?
Core answer: Around a polymorph-defined salt method-of-use patent, the operative landscape typically includes:
- earlier patents on the compound salt (and its discovery)
- polymorph patents that define different forms
- formulation patents for specific dosage forms or delivery routes
- method-of-treatment patents for indications
- patents tied to manufacturing, crystallization, and isolation conditions that yield the claimed polymorph
- regulatory exclusivity that can delay ANDA filings
However: The provided information does not include the chemical identity of Formula II, assignee, priority date, or any related patent numbers, so a complete US family map and Orange Book linkage cannot be stated accurately from the claim text alone.
US 8,557,852 claim-by-claim scope map
| Claim |
Therapeutic target |
Active requirement |
Polymorph definition |
Formulation limitation |
| 1 |
Prevent/treat venous thrombosis |
Formula II salt |
Crystalline polymorph form |
None (administration implied) |
| 2 |
Claim 1 method |
Formula II salt (polymorph) |
Crystalline polymorph form |
Salt in pharmaceutical composition + acceptable carrier |
| 3 |
Claim 1 method |
Formula II salt (polymorph) |
XRPD: at least 4 peaks from set (Claim 3 list) |
None beyond salt/carrying administration |
| 4 |
Claim 1 method |
Formula II salt (polymorph) |
XRPD: at least 8 peaks from set (Claim 4 list) |
None beyond salt/carrying administration |
| 5 |
Claim 1 method |
Formula II salt (polymorph) |
XRPD approximate to FIG. 1A |
None beyond salt/carrying administration |
| 6 |
Claim 1 method |
Formula II salt (polymorph) |
DSC approximate to FIG. 2A |
None beyond salt/carrying administration |
| 7 |
Prevent/treat deep venous thrombosis |
Formula II salt |
Crystalline polymorph form |
None |
| 8 |
Claim 7 method |
Formula II salt (polymorph) |
Crystalline polymorph form |
Salt in pharmaceutical composition + acceptable carrier |
| 9 |
Claim 7 method |
Formula II salt (polymorph) |
XRPD: at least 4 peaks from set (Claim 9 list) |
None beyond administration |
| 10 |
Claim 7 method |
Formula II salt (polymorph) |
XRPD: at least 8 peaks from set (Claim 10 list) |
None beyond administration |
| 11 |
Claim 7 method |
Formula II salt (polymorph) |
XRPD approximate to FIG. 1A |
None beyond administration |
| 12 |
Claim 7 method |
Formula II salt (polymorph) |
DSC approximate to FIG. 2A |
None beyond administration |
What does US 8,557,852 likely cover commercially (product differentiation by polymorph)?
Core answer: The patent’s commercialization protection is strongest against:
- generic makers that cannot crystallize/keep the same solid-state form boundaries away from the claimed polymorph definition, and
- “authorized generic” or branded follow-on products using the same polymorph-defined Formula II salt.
The claims do not hinge on dosing regimen, duration, or route in the text provided. If the clinical indication is venous thrombosis or DVT, the method-of-use coverage can apply across dosing patterns so long as the administered material satisfies the polymorph constraints.
Key Takeaways
- US 8,557,852 is a polymorph-defined salt method-of-use patent for preventing or treating venous thrombosis, including deep venous thrombosis.
- Independent claims are broad on therapeutic purpose but constrained by Formula II salt and a crystalline polymorph form.
- Dependent claims operationalize polymorph identity using XRPD peak-count criteria (at least 4 or at least 8 characteristic peak locations from specified sets) plus XRPD “approximate to” FIG. 1A and DSC “approximate to” FIG. 2A.
- For generic and alternative-polymorph strategies, the main infringement axis is solid-state identity at administration, not merely chemical identity.
- The formulation language is broad (salt + pharmaceutically acceptable carrier), so differentiation hinges on polymorph selection and characterization compliance.
FAQs
1) What makes a solid form infringe XRPD-dependent dependent claims 3/4 (or 9/10)?
Meeting the minimum peak-count thresholds at the specified approximate characteristic 2θ locations, and passing “approximate to” similarity if FIG. 1A is asserted.
2) Can a generic avoid infringement by changing excipients while using the same polymorph salt?
Excipients alone do not avoid infringement if the administered polymorph salt remains within the claimed solid-state identity.
3) Does “approximate to FIG. 1A” require exact peak matching?
No. The claim standard is approximation, so litigation typically turns on expert interpretation of similarity margins and measurement variability.
4) Are DSC constraints mandatory to prove infringement?
DSC constraints are in dependent claims (6 and 12). They are not required for independent-claim infringement but can strengthen the patentee’s proof when asserted.
5) How does the “at least four” vs “at least eight” XRPD structure change risk?
“At least four” is easier to meet (broader polymorph inclusion), while “at least eight” is stricter (narrower matching), affecting which dependent claim theories are available based on the accused pattern.
References
- US Patent 8,557,852. “Method for preventing or treating venous thrombosis” (claims reproduced as provided by user).
